HUE056612T2 - Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével - Google Patents

Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével

Info

Publication number: HUE056612T2
Authority: HU; Hungary
Prior art keywords: gemcitabine; paclitaxel; methods; pancreatic cancer; treating pancreatic
Prior art date: 2013-01-11

Application number

HUE14737791A

Other languages

English (en)

Hungarian (hu)

Inventor

Neil P Desai

Markus Renschler

Original Assignee

Abraxis Bioscience Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-11

Filing date

2014-01-10

Publication date

2022-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51165317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE056612(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-01-10 Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc

2022-02-28 Publication of HUE056612T2 publication Critical patent/HUE056612T2/hu

Links

229930012538 Paclitaxel Natural products 0.000 title 1
206010061902 Pancreatic neoplasm Diseases 0.000 title 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
229960005277 gemcitabine Drugs 0.000 title 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
201000002528 pancreatic cancer Diseases 0.000 title 1
208000008443 pancreatic carcinoma Diseases 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)

HUE14737791A 2013-01-11 2014-01-10 Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével HUE056612T2 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361751820P	2013-01-11	2013-01-11
US201361752355P	2013-01-14	2013-01-14
US13/794,480 US9511046B2 (en)	2013-01-11	2013-03-11	Methods of treating pancreatic cancer

Publications (1)

Publication Number	Publication Date
HUE056612T2 true HUE056612T2 (hu)	2022-02-28

Family

ID=51165317

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE14737791A HUE056612T2 (hu)	2013-01-11	2014-01-10	Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével

Country Status (25)

Country	Link
US (3)	US9511046B2 (2)
EP (1)	EP2943192B9 (2)
JP (3)	JP6342918B2 (2)
KR (1)	KR102205710B1 (2)
CN (2)	CN109793728A (2)
AU (1)	AU2013203699B2 (2)
BR (1)	BR112015016681A8 (2)
CA (1)	CA2897589C (2)
CY (1)	CY1124273T1 (2)
DK (1)	DK2943192T3 (2)
ES (1)	ES2878145T3 (2)
HK (1)	HK1216853A1 (2)
HR (1)	HRP20211062T1 (2)
HU (1)	HUE056612T2 (2)
IL (2)	IL239739A0 (2)
LT (1)	LT2943192T (2)
MX (1)	MX382017B (2)
NZ (2)	NZ734971A (2)
PL (1)	PL2943192T3 (2)
PT (1)	PT2943192T (2)
RS (1)	RS62076B1 (2)
SI (1)	SI2943192T1 (2)
SM (1)	SMT202100377T1 (2)
WO (1)	WO2014110443A1 (2)
ZA (1)	ZA201504877B (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103405405A (zh)	2002-12-09	2013-11-27	阿布拉西斯生物科学有限责任公司	组合物和传递药剂的方法
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl)	2005-02-18	2012-01-31	Abraxis Bioscience Llc	Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
KR101420445B1 (ko)	2005-08-31	2014-07-16	아브락시스 바이오사이언스, 엘엘씨	수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
EP3470071A1 (en)	2006-12-14	2019-04-17	Abraxis BioScience, LLC	Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP5579057B2 (ja) *	2007-06-01	2014-08-27	アブラクシスバイオサイエンス，エルエルシー	再発性癌の処置のための方法および組成物
HRP20192259T1 (hr)	2009-04-15	2020-03-06	Abraxis Bioscience, Llc	Pripravci nanočestica bez priona i metode njihove proizvodnje
CA3051495A1 (en)	2010-03-26	2011-09-29	Abraxis Bioscience, Llc	Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR20130028727A (ko)	2010-03-29	2013-03-19	아브락시스 바이오사이언스, 엘엘씨	치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en)	2010-03-29	2017-12-22	Abraxis Bioscience Llc	Methods of treating cancer
BR112012030909A2 (pt)	2010-06-04	2020-08-18	Abraxis Bioscience, Llc	métodos de tratamento de câncer pancreático
WO2011156119A1 (en) *	2010-06-07	2011-12-15	Abraxis Bioscience, Llc	Combination therapy methods for treating proliferative diseases
JP6038123B2 (ja)	2011-04-28	2016-12-07	アブラクシスバイオサイエンス，エルエルシー	ナノ粒子組成物の脈管内送達およびそれらの使用
JP6216721B2 (ja)	2011-12-14	2017-10-18	アブラクシスバイオサイエンス，エルエルシー	粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
EP3698784A1 (en)	2013-03-12	2020-08-26	Abraxis BioScience, LLC	Methods of treating lung cancer
EP2968191B1 (en)	2013-03-14	2021-06-16	Abraxis BioScience, LLC	Methods of treating bladder cancer
US10527604B1 (en)	2015-03-05	2020-01-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en)	2015-03-05	2020-07-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EP3302423B1 (en)	2015-06-04	2022-05-25	Crititech, Inc.	Particle production system and particle collection device
PL3998069T3 (pl)	2015-06-29	2025-03-31	Abraxis Bioscience, Llc	Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
WO2017003908A1 (en) *	2015-06-30	2017-01-05	The Trustees Of Columbia University In The City Of New York	Talc-bound compositions and uses thereof
BR112018069628A2 (pt)	2016-04-04	2019-02-12	Crititech, Inc.	métodos para tratamento de tumor sólido
EP3595717A1 (en) *	2017-03-17	2020-01-22	Imclone, LLC	Combination therapy for pancreatic cancer
EP3615145B1 (en)	2017-06-09	2024-05-15	Crititech, Inc.	Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en)	2017-06-14	2018-12-20	Crititech, Inc.	Methods for treating lung disorders
KR20250057947A (ko)	2017-10-03	2025-04-29	크리티테크, 인크.	암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
IL277402B1 (en)	2018-03-20	2026-04-01	Abraxis Bioscience Llc	Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
GB201908352D0 (en) *	2019-06-11	2019-07-24	Innovation Ulster Ltd	Sonodynamic therapy
US20220332832A1 (en) *	2019-08-01	2022-10-20	New York University	Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP7832108B2 (ja)	2019-10-28	2026-03-17	アブラクシスバイオサイエンス，エルエルシー	アルブミンおよびラパマイシンの医薬組成物
US20230085602A1 (en) *	2020-02-04	2023-03-16	Swedish Orphan Biovitrum AB (publ )	Pdac treatment regimen
WO2024186320A1 (en) *	2023-03-09	2024-09-12	Minneamrita Therapeutics Llc	Drug combination for treatment of pancreatic cancer
CN117099681B (zh) *	2023-08-28	2024-07-05	南京农业大学	一种利用紫杉醇加倍玉米单倍体的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6528067B1 (en)	1993-02-22	2003-03-04	American Bioscience, Inc.	Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
BR9405798A (pt)	1993-02-22	1995-12-12	Vivorx Pharmaceuticals Inc	Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en)	1993-02-22	2004-06-15	American Bioscience, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en)	1993-03-26	1994-11-08	Vivorx Pharmaceuticals, Inc.	Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US5439686A (en)	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030068362A1 (en)	1993-02-22	2003-04-10	American Bioscience, Inc.	Methods and formulations for the delivery of pharmacologically active agents
US5997904A (en)	1993-02-22	1999-12-07	American Bioscience, Inc.	Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5650156A (en)	1993-02-22	1997-07-22	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US6565842B1 (en)	1995-06-07	2003-05-20	American Bioscience, Inc.	Crosslinkable polypeptide compositions
US20070092563A1 (en)	1996-10-01	2007-04-26	Abraxis Bioscience, Inc.	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en)	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
BRPI9810945B8 (pt)	1997-06-27	2021-05-25	Abraxis Bioscience Inc	formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
CA2369740A1 (en)	1999-04-22	2000-11-02	American Biosciences, Inc.	Long term administration of pharmacologically active agents
CA2684454A1 (en)	1999-05-21	2000-11-18	American Bioscience, Llc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it)	2000-05-18	2001-11-18	Acs Dobfar Spa	Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) *	2002-03-29	2003-09-29	Acs Dobfar Spa	Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
PT1585548T (pt)	2002-12-09	2018-10-17	Abraxis Bioscience Llc	Composições e métodos de administração de agentes farmacológicos
CN103405405A (zh)	2002-12-09	2013-11-27	阿布拉西斯生物科学有限责任公司	组合物和传递药剂的方法
US20070166388A1 (en)	2005-02-18	2007-07-19	Desai Neil P	Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl)	2005-02-18	2012-01-31	Abraxis Bioscience Llc	Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
AU2012201568B2 (en)	2005-02-18	2014-07-31	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
EP1874296A4 (en)	2005-04-29	2010-06-30	Kosan Biosciences Inc	METHOD FOR THE TREATMENT OF SEVERAL MYELOMES USING 17-AAG OR 17-AG OR PRODRUGS OR ALL
AU2006284657B2 (en)	2005-08-31	2012-07-19	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR101420445B1 (ko)	2005-08-31	2014-07-16	아브락시스 바이오사이언스, 엘엘씨	수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
JP2007297339A (ja) *	2006-04-29	2007-11-15	Torii Yakuhin Kk	癌を治療又は検査するための医薬
BRPI0622006A2 (pt)	2006-08-31	2011-12-20	Abraxis Bioscience Llc	usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
EP3470071A1 (en)	2006-12-14	2019-04-17	Abraxis BioScience, LLC	Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008109163A1 (en)	2007-03-07	2008-09-12	Abraxis Bioscience, Llc.	Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en)	2007-05-03	2010-07-01	Desai Neil P	Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja)	2007-06-01	2014-08-27	アブラクシスバイオサイエンス，エルエルシー	再発性癌の処置のための方法および組成物
JP2011517683A (ja)	2008-04-10	2011-06-16	アブラクシスバイオサイエンス，エルエルシー	疎水性タキサン誘導体の組成物およびその使用
MX2010011165A (es)	2008-04-10	2011-02-22	Abraxis Bioscience Llc	Composiciones de derivados de taxano hidrofobos y sus usos.
EP2276509B1 (en) *	2008-04-11	2016-06-15	Seattle Genetics, Inc.	Detection and tratment of pancreatic, ovarian and other cancers
NZ593343A (en)	2008-12-11	2013-04-26	Abraxis Bioscience Llc	Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
GB0900555D0 (en) *	2009-01-14	2009-02-11	Topotarget As	New methods
CN102427728A (zh)	2009-03-13	2012-04-25	阿布拉科斯生物科学有限公司	用硫代秋水仙碱衍生物进行联合治疗
EP2416650B1 (en)	2009-04-10	2020-02-26	Abraxis BioScience, LLC	Nanoparticle formulations and uses therof
HRP20192259T1 (hr)	2009-04-15	2020-03-06	Abraxis Bioscience, Llc	Pripravci nanočestica bez priona i metode njihove proizvodnje
US8383358B2 (en) *	2009-05-28	2013-02-26	Abraxis Bioscience, Llc	Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
PL2470173T3 (pl) *	2009-08-25	2016-11-30		Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
JP2011079788A (ja) *	2009-10-08	2011-04-21	Oita Univ	膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
WO2011083464A2 (en) *	2010-01-05	2011-07-14	Vascular Biogenics Ltd.	Methods for use of a specific anti-angiogenic adenoviral agent
CA3051495A1 (en)	2010-03-26	2011-09-29	Abraxis Bioscience, Llc	Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
KR20130028727A (ko)	2010-03-29	2013-03-19	아브락시스 바이오사이언스, 엘엘씨	치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en)	2010-03-29	2017-12-22	Abraxis Bioscience Llc	Methods of treating cancer
US20130005678A1 (en)	2010-03-30	2013-01-03	Clavis Pharma Asa	Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
WO2011153009A1 (en)	2010-06-02	2011-12-08	Abraxis Bioscience, Llc	Methods of treating bladder cancer
BR112012030909A2 (pt)	2010-06-04	2020-08-18	Abraxis Bioscience, Llc	métodos de tratamento de câncer pancreático
WO2011156119A1 (en)	2010-06-07	2011-12-15	Abraxis Bioscience, Llc	Combination therapy methods for treating proliferative diseases
JP6038123B2 (ja)	2011-04-28	2016-12-07	アブラクシスバイオサイエンス，エルエルシー	ナノ粒子組成物の脈管内送達およびそれらの使用
JP6216721B2 (ja)	2011-12-14	2017-10-18	アブラクシスバイオサイエンス，エルエルシー	粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US20140186447A1 (en)	2012-12-28	2014-07-03	Abraxis Bioscience, Llc	Nanoparticle compositions of albumin and paclitaxel
US20140199405A1 (en)	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on mutation status of k-ras
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
US20140199404A1 (en)	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on level of a nucleoside transporter
EP2953622B1 (en)	2013-02-11	2021-03-24	Abraxis BioScience, LLC	Methods of treating melanoma
EP3698784A1 (en)	2013-03-12	2020-08-26	Abraxis BioScience, LLC	Methods of treating lung cancer
CN105209035A (zh)	2013-03-13	2015-12-30	阿布拉科斯生物科学有限公司	治疗儿童实体瘤的方法
EP2968191B1 (en)	2013-03-14	2021-06-16	Abraxis BioScience, LLC	Methods of treating bladder cancer
US20170202782A1 (en)	2014-04-06	2017-07-20	Abraxis Bioscience, Llc	Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US20180064679A1 (en)	2015-03-05	2018-03-08	Abraxis Bioscience, Llc	Method for treating cancer based on level of glucocorticoid receptor
PL3998069T3 (pl)	2015-06-29	2025-03-31	Abraxis Bioscience, Llc	Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
US20180177771A1 (en)	2015-06-29	2018-06-28	Abraxis Bioscience, Llc	Biomarkers for nanoparticle compositions
HK1247093A1 (zh)	2015-06-29	2018-09-21	阿布拉科斯生物科学有限公司	使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
US20170181988A1 (en)	2015-12-23	2017-06-29	Cipla Limited	Methods for the treatment of bladder cancer

2013
- 2013-03-11 US US13/794,480 patent/US9511046B2/en active Active
- 2013-04-11 AU AU2013203699A patent/AU2013203699B2/en active Active
2014
- 2014-01-10 ES ES14737791T patent/ES2878145T3/es active Active
- 2014-01-10 RS RS20210823A patent/RS62076B1/sr unknown
- 2014-01-10 BR BR112015016681A patent/BR112015016681A8/pt not_active Application Discontinuation
- 2014-01-10 JP JP2015552834A patent/JP6342918B2/ja active Active
- 2014-01-10 CN CN201910067315.0A patent/CN109793728A/zh active Pending
- 2014-01-10 CN CN201480013217.4A patent/CN105025893A/zh active Pending
- 2014-01-10 LT LTEP14737791.5T patent/LT2943192T/lt unknown
- 2014-01-10 SM SM20210377T patent/SMT202100377T1/it unknown
- 2014-01-10 HK HK16104890.5A patent/HK1216853A1/zh unknown
- 2014-01-10 CA CA2897589A patent/CA2897589C/en active Active
- 2014-01-10 EP EP14737791.5A patent/EP2943192B9/en not_active Revoked
- 2014-01-10 PL PL14737791T patent/PL2943192T3/pl unknown
- 2014-01-10 KR KR1020157021320A patent/KR102205710B1/ko active Active
- 2014-01-10 HU HUE14737791A patent/HUE056612T2/hu unknown
- 2014-01-10 WO PCT/US2014/011145 patent/WO2014110443A1/en not_active Ceased
- 2014-01-10 PT PT147377915T patent/PT2943192T/pt unknown
- 2014-01-10 NZ NZ734971A patent/NZ734971A/en unknown
- 2014-01-10 HR HRP20211062TT patent/HRP20211062T1/hr unknown
- 2014-01-10 NZ NZ630230A patent/NZ630230A/en unknown
- 2014-01-10 DK DK14737791.5T patent/DK2943192T3/da active
- 2014-01-10 MX MX2015008898A patent/MX382017B/es unknown
- 2014-01-10 SI SI201431853T patent/SI2943192T1/sl unknown
2015
- 2015-07-01 IL IL239739A patent/IL239739A0/en unknown
- 2015-07-07 ZA ZA2015/04877A patent/ZA201504877B/en unknown
2016
- 2016-10-06 US US15/287,613 patent/US9855220B2/en active Active
2017
- 2017-11-21 US US15/820,022 patent/US10328031B2/en active Active
2018
- 2018-02-21 JP JP2018028611A patent/JP6697017B2/ja active Active
2019
- 2019-02-27 JP JP2019033910A patent/JP2019081790A/ja active Pending
2020
- 2020-02-26 IL IL272905A patent/IL272905A/en unknown
2021
- 2021-06-30 CY CY20211100585T patent/CY1124273T1/el unknown

Also Published As

Publication number	Publication date
SMT202100377T1 (it)	2022-01-10
EP2943192A1 (en)	2015-11-18
CN105025893A (zh)	2015-11-04
EP2943192B9 (en)	2021-09-29
JP6342918B2 (ja)	2018-06-13
HRP20211062T1 (hr)	2021-12-24
NZ734971A (en)	2018-12-21
ZA201504877B (en)	2016-10-26
NZ630230A (en)	2017-09-29
SI2943192T1 (sl)	2021-09-30
CA2897589A1 (en)	2014-07-17
JP2019081790A (ja)	2019-05-30
CY1124273T1 (el)	2022-11-25
KR102205710B1 (ko)	2021-01-21
IL239739A0 (en)	2015-08-31
JP2018087235A (ja)	2018-06-07
AU2013203699B2 (en)	2016-09-08
ES2878145T3 (es)	2021-11-18
US9511046B2 (en)	2016-12-06
BR112015016681A8 (pt)	2019-10-22
WO2014110443A1 (en)	2014-07-17
US10328031B2 (en)	2019-06-25
EP2943192B1 (en)	2021-05-12
JP2016505018A (ja)	2016-02-18
RS62076B1 (sr)	2021-07-30
LT2943192T (lt)	2021-08-10
BR112015016681A2 (pt)	2017-07-11
AU2013203699A1 (en)	2014-10-30
MX382017B (es)	2025-03-11
EP2943192A4 (en)	2016-06-01
US9855220B2 (en)	2018-01-02
IL272905A (en)	2020-04-30
CA2897589C (en)	2021-03-02
MX2015008898A (es)	2015-10-14
KR20150103745A (ko)	2015-09-11
HK1216853A1 (zh)	2016-12-09
DK2943192T3 (da)	2021-07-05
PL2943192T3 (pl)	2022-01-24
JP6697017B2 (ja)	2020-05-20
CN109793728A (zh)	2019-05-24
US20180153820A1 (en)	2018-06-07
PT2943192T (pt)	2021-07-16
US20140199403A1 (en)	2014-07-17
US20170020824A1 (en)	2017-01-26

Publication	Publication Date	Title
HUE056612T2 (hu)	2022-02-28	Hasnyálmirigyrák kezelésének eljárásai paclitaxel és gemcitabin segítségével
HUE047699T2 (hu)	2020-05-28	Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
DK3076972T3 (da)	2022-01-03	Cancerbehandling med kombination af plinabulin og taxan
IL245337B (en)	2022-05-01	Combinations of checkpoint inhibitors and therapeutics to treat cancer
IL246038B (en)	2020-10-29	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
LT3277842T (lt)	2019-10-25	Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
DK4000608T3 (da)	2026-02-09	Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BR112015028115A2 (pt)	2017-10-17	métodos e composições para o tratamento de câncer
MA41997A (fr)	2021-03-31	Combinaisons de cannabinoïdes et de n-acyléthanolamines
PL3198009T3 (pl)	2022-01-24	Onkolityczne wirusy nowotworowe i sposoby zastosowania
IL257785B (en)	2022-04-01	Methods of diagnosing and treating conduct disorder
PL3838271T3 (pl)	2025-12-15	Leczenie podwyższonych poziomów eozynofili i/lub bazofili
PL3200815T3 (pl)	2021-10-18	Sposoby i kompozycje do leczenia nowotworu
HUE046728T2 (hu)	2020-03-30	Rák és jóindulatú proliferációs rendellenességek kezelése
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
IL243728A0 (en)	2016-04-21	Heterobicycloaryl rorc2 inhibitors and methods of use thereof
IL240688A0 (en)	2015-10-29	Pancreatic cancer treatment methods
PL3397967T3 (pl)	2021-06-28	Kompozycje i sposoby do wykrywania i leczenia raka przełyku
DK3042669T3 (da)	2023-06-12	Antitumormiddel og forstærker af antitumorvirkning
IL254825A0 (en)	2017-12-31	Methods of treatment with taselisib
PL3082845T3 (pl)	2021-08-02	Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2948137T3 (pl)	2019-02-28	Sposoby leczenia zwłóknienia i nowotworów
PL2970463T3 (pl)	2018-04-30	Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
IL246270A0 (en)	2016-07-31	Differential assembly and method
DK3076988T3 (da)	2019-09-16	Farmaceutiske sammensætninger og fremgangsmåder til behandling og forebyggelse af metastatisk cancer